Trial results for amivantamab in patients with recurrent and metastatic adenoid cystic carcinoma were posted on ClinicalTrials.gov on 2026-05-08. The study reported an overall response rate in 1 of 21 participants, with a median progression-free survival of 4.6 months.
Background
Adenoid cystic carcinoma is a rare form of salivary gland cancer. The study investigated amivantamab in patients with recurrent and metastatic forms of this disease, where treatment options can be limited.
Trial design
This Phase 2 study (NCT05074940) enrolled 21 participants with recurrent and metastatic adenoid cystic carcinoma, a type of salivary gland cancer. The trial's purpose was to determine the efficacy of amivantamab in this patient population. Key outcomes measured included overall response rate and progression-free survival.
Key results
- The overall response rate, measured by RECIST criteria, was observed in 1 participant out of 21.
- The median progression-free survival was 4.6 months.
- Adverse events were reported in 21 participants, indicating all enrolled participants experienced at least one adverse event.
- Genetic mutations were identified in 14 participants.
- Quality of life, measured via FACT-HN, showed a mean change of -0.7 units with a standard deviation of 8.4 units.
What this means
The results from this Phase 2 trial suggest limited objective responses to amivantamab in patients with recurrent and metastatic adenoid cystic carcinoma, with only 1 participant achieving an overall response. The median progression-free survival of 4.6 months provides insight into the duration of disease control. The high incidence of adverse events, affecting all 21 participants, highlights the safety profile observed in this study population. Further research would be needed to understand the specific patient subsets that might benefit from this therapy and to contextualize these findings within the broader treatment landscape for this rare cancer.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05074940, titled "Amivantamab in Adenoid Cystic Carcinoma," were posted on 2026-05-08 on clinicaltrials.gov.